Priority Applications (3) Applications Claiming Priority (4) Publications (1) Family ID=50100453 Family Applications (1) Country Status (5) Cited By (2) Families Citing this family (3) Citations (3) 2013 2013-09-27 WO PCT/US2013/062199 patent/WO2014052766A1/en not_active Ceased 2013-09-27 US US14/038,973 patent/US9051351B2/en active Active 2015 2015-03-26 SA SA515360200A patent/SA515360200B1/en unknown 2015-03-26 IL IL237966A patent/IL237966A0/en unknown 2015-04-14 ZA ZA2015/02504A patent/ZA201502504B/en unknown
Several natural products, such as sorghum bran extract , white mulberry leaf extract , brown seaweed extract , and cinnamon extract, may also promote optimal glucose metabolism and help users attain healthy glycemic control (Andallu 2001
That is why our team evaluates your full picture, hormones, inflammatory markers, metabolic status, sleep, and cognitive baseline, before discussing whether a research peptide fits
It remains an investigational drug currently being evaluated in Phase 3 clinical trials by Eli Lilly for the treatment of: Obesity (without diabetes) Type 2 diabetes Nonalcoholic fatty liver disease (NAFLD/NASH) Projected Approval Timeline Based on Phase 2 success and accelerated trials, Retatrutide could receive FDA approval as early as 2026 Eli Lilly is positioning it to directly compete with Tirzepatide (Mounjaro) and Semaglutide (Wegovy) Expected to be administered as a once-weekly injection Not Available for Research or Off-Label Use Retatrutide is not legally available on the gray market No legitimate research chemical suppliers offer it any listings claiming to sell Retatrutide are likely counterfeit or misbranded Because of its complex multi-receptor structure, DIY compounding is extremely risky and discouraged Athletic Use and WADA Considerations Like other GLP-1 agonists, Retatrutide is not currently banned by WADA However, its performance-enhancing effects (fat loss, appetite suppression, metabolic acceleration) could put it under scrutiny in the future Athletes in tested federations should proceed cautiously once the drug is commercialized Until Retatrutide clears regulatory approval, its use remains confined to clinical trial settings
